Mitsubishi Corporation (“MC”) will strengthen its medical device import and distribution business by expanding its product offerings for medical institutions.  As part of this strategy, Mitsubishi Corporation has agreed today with Kobayashi Pharmaceutical to acquire 80% of Kobayashi Medical, a wholly-owned subsidiary of Kobayashi Pharmaceutical. 

With the aging of society, companies involved in the medical field are increasingly seeking to offer safe medical devices to treat lifestyle diseases such as cancer as well as myocardial infarction, strokes, and bone fractures. 

MC is involved in the import and distribution of medical devices through its group company, which mainly handles endoscopes and surgical instruments in minimally invasive surgery and urology. 

Teaming up with Kobayashi Medical, which handles bone fracture treatment equipment and surgical instruments, will enable MC to offer a wider range of devices and products. In addition, MC is aiming to expand Kobayashi Medical’s business by leveraging MC’s global network and partnerships with its group companies. 

Through the medical field business, Mitsubishi Corporation is working to create sustainable corporate value by contributing to economic and social development.

source : http://www.mitsubishicorp.com/jp/en/pr/archive/2012/html/0000014586.html

Misonix Announces New Distribution Agreement For PanamaFARMINGDALE, N.Y., April 24, 2012 /PRNewswire via COMTEX/ --Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spine surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, has entered into a new, three year, exclusive distribution agreement with Neuro Dynamics S.A. for the distribution of the SonaStar® Ultrasonic Surgical Aspirator and the BoneScalpel(TM) Ultrasonic Bone Cutter. The agreement provides Neuro Dynamics with the right to sell throughout Panama. Included in the agreement are annual minimum purchase requirements. Product training is complete and open market sales have commenced.

Neuro Dynamics is well established in the fields of spine surgery and neurosurgery with a well-earned reputation for successfully introducing state-of-the-art technology to the market in Panama. Their commitment to product support and education is consistent with the core values of Misonix.

The SonaStar is used by neurosurgeons and general surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

"We are very pleased to add Neuro Dynamics to our rapidly expanding, broad-based Latin American distribution team. Their reputation for successfully introducing new technologies to the Panamanian healthcare community is well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We are particularly pleased that they will be selling two of our key products throughoutPanama."

About Misonix Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic surgical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contacts

Misonix Contact:

Lytham Partners, LLC

Richard Zaremba

Robert Blum, Joe Dorame, Joe Diaz

631-694-9555

602-889-9700

invest@misonix.com

mson@lythampartners.com

SOURCE Misonix, Inc
http://phx.corporate-ir.net/phoenix.zhtml?c=117022&p=irol-newsArticle&ID=1686426&highlight=

EXTON, Pa., April 24, 2012 /PRNewswire/ -- Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical procedures, today announced the achievement of several milestones for its Meso BioMatrix™ surgical mesh including the first clinical implant of the product. The Meso BioMatrix™ product is indicated for use in the United States for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair and reinforcement in plastic and reconstructive surgery.   The procedure was performed by Dennis Hammond, M.D. of Partners in Plastic Surgery in Grand Rapids, Michigan.  "The Meso BioMatrix™ product offers several advantages for use in plastic and reconstructive surgery including strength with just the right amount of pliability, and easy re-draping around corners and complex contours. It will serve as an excellent adjunct in plastic and reconstructive surgery," commented Dr. Hammond.

Kensey Nash will be exhibiting the Meso BioMatrix™ product May 5th-7th at the American Society of Aesthetic Plastic Surgery Meeting in Vancouver, BC. 

The Meso BioMatrix™ surgical mesh is manufactured using Kensey Nash's proprietary Optrix™ process, which gently disinfects tissues, inactivates viruses and removes cells while preserving extracellular matrix (ECM) components.  It is a unique tissue derived from porcine peritoneum, with a thinner profile, and desirable handling characteristics. Pre-clinical studies have shown more rapid cellular infiltration when compared to dermis based xenograft materials[1].

In addition, Kensey Nash has received 510k clearance for its Meso BioMatrix™ Wound Matrix. This clearance allows for the use of the Meso BioMatrix™ device in the management of topical wounds. Next steps for the technology include CE Mark submissions for both wound and breast surgery applications, and the initiation of an Investigational Device Exemption (IDE) feasibility clinical study for the use of Meso BioMatrix™ for soft tissue reinforcement in two-stage post-mastectomy breast reconstruction surgery. The Company has received conditional approval on the IDE protocol from the FDA and has begun clinical site qualifications.  

 "The Meso BioMatrix™ products and the previously launched porcine dermis products demonstrate the versatility of the OPTRIX™ processing technology to provide a full spectrum of ECM products with a diverse range of properties for multiple surgical applications.  Surgeons have responded favorably to now having an option of biologic materials to meet an array of surgical needs. We anticipate that these efforts will allow Kensey Nash to explore various partnership opportunities in these growing biologic markets," commented Doug Evans, Chief Operating Officer.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology. The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials. The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopaedic, sports medicine, spine, endovascular and general surgery markets.

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, the Company's continued success in its research and development efforts in its cartilage repair and extracellular matrix technologies programs, the Company's ability to enter into new partnering relationships with respect to its extracellular matrix products and the success of existing and new partners in selling the Company's extracellular matrix products, the completion of additional clinical trials in both the U.S. andEurope to support regulatory approval of future generations of its products and competition from other technologies, current economic conditions, and foreign currency fluctuations. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosures under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.


[1] Data on file at Kensey Nash

Meso BioMatrix™ and Optrix™ are trademarks of Kensey Nash Corporation



SOURCE Kensey Nash Corporation

http://www.kenseynash.com

BELGRADE, Mont., April 24, 2012 /PRNewswire via COMTEX/ --Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has secured an accounts receivable credit facility with Midcap Financial LLC and Silicon Valley Bank. The revolving loan credit facility allows Bacterin to borrow up to $5 millionthrough January 1, 2015. The facility allows borrowings based upon a predetermined formula of up to 80% of Bacterin's eligible accounts receivable, as defined in the credit and security agreement.

"Due to the high working capital needs of our business associated with the necessity for our inventory to be consigned to our hospital accounts, the accounts receivable facility is an efficient way for Bacterin to access cash, from time to time, without diluting equity," said Guy Cook, Chairman and CEO of Bacterin. "Our strong relationships with Silicon Valley Bank and Midcap Financial helped us to secure this non-dilutive financing option, as we prepare for the next stage of growth at Bacterin International."

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.

About MidCap Financial, LLC

MidCap Financial is a commercial finance company focused on middle market lending in the broad national healthcare industry. MidCap specializes in $5 million to $200 million loans. The company is headquartered in Bethesda, MD, with offices in Chicagoand Los Angeles, and focuses in four areas:

Asset-Based working capital loans to healthcare providers collateralized by third-party accounts receivable and other assets;

Leveraged loans to healthcare companies backed by private equity sponsors;

Life Sciences loans to VC-backed and public pharmaceutical, biotech, and medical device companies;

Real Estate loans to skilled nursing facilities, senior housing properties, and medical office buildings

Additional information about MidCap Financial can be found atwww.midcapfinancial.com

About Silicon Valley Bank

Silicon Valley Bank is the premier bank for technology, life science, cleantech, venture capital, private equity and premium wine businesses. SVB provides industry knowledge and connections, financing, treasury management, corporate investment and international banking services to its clients worldwide through 27 U.S. offices and seven international operations. (Nasdaq: SIVB) www.svb.com.

Silicon Valley Bank is the California bank subsidiary and the commercial banking operation of SVB Financial Group. Banking services are provided by Silicon Valley Bank, a member of the FDIC and the Federal Reserve System. SVB Private Bank is a division of Silicon Valley Bank. SVB Financial Group is also a member of the Federal Reserve System.

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

INVESTOR INQUIRIES:

Hayden IR

James Carbonara, Regional Vice President, 646-755-7412

james@haydenir.com

Brett Maas, 646-536-7331

brett@haydenir.com

SOURCE 
Bacterin International Holdings, Inc.
http://investor.bacterin.com/phoenix.zhtml?c=234008&p=irol-newsArticle&ID=1686340&highlight=